+
Sun Pharma to Declare Q4 Results on May 22, 2025
ECONOMY & POLICY

Sun Pharma to Declare Q4 Results on May 22, 2025

Sun Pharmaceutical Industries will announce results for the fourth quarter ended March 31, 2025, on May 22, 2025. The Company will conduct an hour-long call at 06.30 pm IST on May 22, 2025, where senior management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please pre-register yourself on the below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Sun Pharma is the world’s leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations.

Sun Pharmaceutical Industries will announce results for the fourth quarter ended March 31, 2025, on May 22, 2025. The Company will conduct an hour-long call at 06.30 pm IST on May 22, 2025, where senior management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please pre-register yourself on the below link and dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.Sun Pharma is the world’s leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations.

Next Story
Infrastructure Urban

GRM Overseas Reports Q1 FY26 Results; Strengthens Global & Domestic Presence

GRM Overseas has announced its unaudited financial results for the quarter ended 30 June 2025. The company reported a positive performance in terms of margins and profitability, despite topline pressures from global geopolitical challenges.Atul Garg, Managing Director, said:"We have maintained healthy margins and profitability while navigating short-term headwinds. Our focus remains on expanding our product portfolio, enhancing brand visibility, and deepening our distribution network. Internationally, we continue to hold a strong position in the Basmati rice export market, particularly in the ..

Next Story
Infrastructure Urban

Zuari Industries Posts Q1 FY26 Revenue Growth; PAT Turns Positive

Zuari Industries has announced its audited financial results for the quarter ended 30 June 2025.On a standalone basis, the company reported Revenue from Operations of Rs 2.10 billion and Operating EBITDA of Rs 220.4 million. Standalone Profit Before Tax (PBT), before exceptional items, stood at Rs 90 million.On a consolidated basis, Revenue rose 10.5 per cent year-on-year to Rs 2.67 billion, while Profit After Tax (PAT) stood at Rs 50 million compared to a loss of Rs 330.6 million in Q1 FY25.Segment HighlightsSugar, Power & Ethanol: Operations were impacted by an early mill closure due to ..

Next Story
Infrastructure Urban

Karnataka Bank Reports Q1 FY26 Net Profit of Rs 2.92 Bn

Karnataka Bank has announced a net profit of Rs 2.92 billion for the first quarter of FY26, compared to Rs 4 billion in Q1 FY25. The results were approved at the Board of Directors meeting held on 13 August 2025 at the Bank’s headquarters in Mangaluru.Asset Quality & Capital AdequacyGross NPA: 3.46 per cent, improved from 3.54 per cent in Q1 FY25.Net NPA: 1.44 per cent, down from 1.66 per cent in Q1 FY25.Capital Adequacy Ratio (CAR): 20.46 per cent, up from 17.64 per cent in Q1 FY25.Announcing the results, Raghavendra S Bhat, Managing Director & CEO, said:"The Bank has registered a m..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?